Company intelligence / Profile preview

Seraph Research Institute

Toluca Lake, California, United States

Ownership: Private
Development stage: Other

Overview

SRI has developed a novel adoptive cell therapy for HIV (utilizing natural killer and gamma delta T-cells from healthy donors) that demonstrated promising results in a patient with otherwise uncontrolled HIV, achieving undetectable viral load without antiretroviral therapy for an extended period; the program has a Pre-IND meeting with the FDA scheduled[4].

Therapeutic areas: Infectious Diseases
Modalities: Cell therapy
Industry: Academic Hospital/University/Research

Partnerships

Enochian BioSciences

Beyond the preview

Go deeper on Seraph Research Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seraph Research Institute.

Explore the full profile